Harrow Health (HROW) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Harrow Announces Second Quarter 2023 Financial Results
August 9, 2023 4:01 PM EDTSecond Quarter 2023 and Recent Selected Highlights:
Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter. GAAP net loss of ($4.2) million. Record adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 million in the prioryear quarter and an increase of 108% over $5.3 million in the sequential quarter. Completed public offering of common stock for aggregate gross proceeds of $69 million. Expanded Oaktree Loan from $100 million to $112.50 million. Acquired certain commercial rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands... More